Indaptus Therapeutics is trading 5.74% up at $1.29, with no confirmed company-specific catalyst identified for the September 8, 2026 move.
- The stock rose 5.17% to $1.22 on September 4.
- The latest reported filing involved a routine board-member resignation.
- Broader U.S. markets were modestly lower, offering no clear market-wide explanation; the move appears driven by trading activity rather than verified news.